BP.06). 1.8% 11.7% ( P
|
|
- Gerald Fisher
- 5 years ago
- Views:
Transcription
1 AJH 2000;13: Electronic Pill-Boxes in the Evaluation of Antihypertensive Treatment Compliance: Comparison of Once Daily Versus Twice Daily Regimen Michel Andrejak, Nathalie Genes, Laurent Vaur, Pascal Poncelet, Pierre Clerson, and Alain Carré The objective was to compare the compliance of hypertensive patients treated with captopril twice daily or trandolapril once daily. After a 2-week placebo period, hypertensive patients (diastolic BP mm Hg) were randomly allocated to trandolapril 2 mg once daily or to captopril 25 mg twice daily for 6 months. and captopril were packed in electronic pill-boxes equipped with a microprocessor that recorded date and time of each opening (MEMS ). Patients compliance was assessed both by standard pillcount and by electronic monitoring. Blood pressure was measured using a validated semi-automatic device at the end of the placebo period and of the treatment period. One hundred sixty-two patients entered the study. Compliance data were evaluable for 133 patients (62 in the captopril group and 71 in the trandolapril group). Treatment groups were comparable at baseline except for age (P.046). Using electronic pill-box, overall compliance was 98.9% in the trandolapril group and 97.5% in the captopril group (P.002). The percentage of missed doses was 2.6% in the trandolapril group and 3.3% in the captopril group (P.06). The percentage of delayed doses was 1.8% in the trandolapril group and 11.7% in the captopril group (P.0001). The percentage of correct dosing periods, ie, a period with only one correct recorded opening, was 94.0% in the trandolapril group and 78.1% in the captopril group (P.0001). Results were unchanged when adjusted for age. At the end of the study, 41% of patients in the trandolapril group and 27% in the captopril group (NS) had their blood pressure normalized (systolic BP <140 and diastolic BP <90 mm Hg). In this 6-month study, the electronic pill-box allowed refined analysis of compliance of hypertensive patients. Patients compliance with once daily trandolapril was higher than with twice daily captopril. The between-group difference is mainly explained by an increase in delayed doses in the twice daily group. Am J Hypertens 2000;13: American Journal of Hypertension, Ltd. KEY WORDS: Electronic pill-box, pill-count, treatment compliance, ACE inhibitor, treatment regimen. Received February 1, Accepted June 8, From the Service de Pharmacologie Clinique, Amiens, France (MA); Laboratoires Roussel Diamant, Medical Department, Paris, France (NG, LV); CMC Darcy, Henin-Beaumont, France (PP); Orgamétrie, Mouvaux, France (PC); and Hôpital Cardiologique, Lille, France (AC). Address correspondence and reprint requests to Dr. Nathalie Genès, Laboratoires Roussel Diamant, Tour HMR, 1 Terrasse Bellini Paris la Défense Cedex, France by the American Journal of Hypertension, Ltd /00/$20.00 Published by Elsevier Science, Inc. PII S (99)
2 AJH FEBRUARY 2000 VOL. 13, NO. 2 COMPLIANCE AND TREATMENT REGIMEN 185 In asymptomatic chronic diseases such as hypertension, treatment compliance is frequently low and difficult to improve. 1 Low compliance has been associated with poorer clinical prognosis. Interruption of drug intake by the patient will bring about a period without effective drug activity. 2 In certain cases the sudden stopping of therapy might well lead to potentially serious withdrawal symptoms, including major cardiovascular complications. 3 6 On the other hand, excessive drug effects might occur when dosing is suddenly resumed. 2 Adequate measurement of compliance is an important challenge. The patient s self-report as well as pillcount are usually used, due to their costs and facility. The use of sophisticated techniques such as biologic assays is restricted to research. All these methods have shown their limitations. 7 9 The development of electronic monitors for medication bottles that register the date and the time of each opening constitutes a marked improvement. 10 Unlike the previously described methods, such devices allow information on the time interval between the doses of medication. Adherence to the instructions regarding treatment may thus be assessed. 11 The MACH 3 study is a part of the French MACH (Medication event monitoring system for the Assessment of the Compliance of Hypertensives) research program. The MACH 1 and MACH 2 studies aimed to determine factors affecting the short-term compliance of hypertensive patients treated with a once daily ACE inhibitor. 12,13 The aim of the present study was to compare the compliance of hypertensive patients treated either with captopril twice daily or trandolapril once daily. PATIENTS AND METHODS Patients Patients aged 18 or over with mild to moderate essential hypertension were eligible for this study. After a 2-week single-blind placebo run-in period, the patients with an office sphygmomanometer diastolic blood pressure (DBP) between 95 and 115 mm Hg were included in the study. The main exclusion criteria were: any serious chronic disease, known hypersensitivity or contraindication to ACE inhibitors, impaired renal function (serum creatinine 130 mol/l), dyskalaemia, and concomitant antihypertensive drug intake. All patients gave their written informed consent. The protocol was approved by the Comité Consultatif de Protection des Personnes se prêtant à la Recherche Biomédicale of Amiens, France (Ethics Committee). Study Design This was a multicenter, nonblinded, randomized, parallel-group study. At the screening visit, eligibility criteria were assessed, written informed consent was obtained, and all present antihypertensive drug therapy was discontinued. After a 2-week placebo run-in period, eligible patients were randomly allocated to either trandolapril, 2 mg once daily, or captopril, 25 mg twice daily, for 6 months according to the parallel design. The patients were told to take their medication at 8:00 am for the trandolapril group, whereas for the captopril group, the patients were told to take their medication at 8:00 am and at 8:00 pm. In nonresponder patients (diastolic BP 90 mm Hg or diastolic BP decrease 10 mm Hg) on the 60th day or on the 120th day, furosemide (20 40 mg) was added. Measurement of Compliance Assessed by MEMS A Medication Event Monitoring System (MEMS, Aprex Corporation, Fremont, CA) was used to assess compliance patterns during the active treatment phase of the study. and captopril were packed in standard pill bottles fitted with a specialized cap containing a microprocessor, which registers date, time, and duration of each opening of the cap. Patients were made aware of its presence and purpose. Patients were given instructions in how to use the special cap on their medication bottles. They were instructed to open the pill bottle only to take their pill. Each patient had the same electronic cap throughout the study and the containers were only changed at Day 60 and Day 120. For each patient, all calculations were derived from the date and the time of each opening. Each opening recorded by the pill-box was considered a single dose intake. We defined for captopril patients two 12-h dosing periods: 2:00 am 1:59 pm and 2:00 pm 1:59 am, whereas for trandolapril patients a single 24-h dosing period (2:00 am 1:59 am) was defined. Four quantitative indices were used to assess the individual compliance: overall compliance, missed doses, delayed doses, and correct dosing periods. Overall compliance was defined by the number of pill-box openings. Missed doses were defined by the absence of recorded openings during the defined dosing periods. Delayed doses were defined by the opening of the pill bottle more than 26 h after the preceding opening for the patients receiving the once daily regimen (trandolapril). For patients receiving the twice daily regimen (captopril), an interval of more than 13 h defined a delayed dose. A dosing period was seen to be correct when including one single correct recorded opening (ie, without a missed dose, a delayed dose, or an extra dose). So dosing periods were judged correct when a single opening occurred within 13 h (captopril) or 26 h (trandolapril) after the preceding dose. Overall compliance, missed doses, delayed doses, and correct dosing periods were expressed as
3 186 ANDREJAK ET AL AJH FEBRUARY 2000 VOL. 13, NO. 2 percentages of prescribed doses (treatment duration number of daily doses). Measurement of Compliance Assessed by Pill-Count Standard pill-count was also used to assess compliance. At each visit, the number of handed-in pills in the containers was counted. Compliance was defined by the number of pills taken (dispensed pills minus returned pills) in relation to the theoretical number of prescribed doses and was expressed as a percentage. Blood Pressure Measurements Sphygmomanometer office blood pressure was recorded at the end of the placebo run-in period to check that inclusion criteria had been met. Physicians were asked to perform, using a mercury sphygmomanometer, three consecutive measurements while the patients were in the sitting position after a 5-min rest. The systolic blood pressure (SBP) was defined using phase I of the Korotkoff s sound and DBP by phase V. The average of the three readings was defined as office SBP and DBP. Automatic office blood pressure was performed by the physician at the end of the placebo run-in period, at each follow-up visit (Day 60, Day 120), and at the end of the active treatment period (Day 180). Three consecutive measurements were performed with the patient in the sitting position after a 5-min rest using thea& DUA751 device (A & D Engineering, Milipitas, CA). This device is a printer-equipped, semi-automatic, digitized one and uses the oscillometric method. It was previously validated by comparison with a random-zero mercury sphygmomanometer. 14 The average of the three readings was used to define the automatic SBP and DBP. These automatic blood pressure data were used to assess antihypertensive efficiency. Data Processing and Statistical Analysis At the end of the study, data retrieval and analysis for MEMS was done through specific Aprex software. Compliance data were then entered into a SAS data set (SAS Institute, Cary, NC). Quantitative data were expressed in terms of means SD and were compared using Student s t test (intergroup comparisons). Qualitative variables were expressed as percentages and were compared using a 2 test. As compliance data did not follow a normal distribution, they were expressed by their median and 10th and 90th percentiles and were compared using the Wilcoxon test. The statistical significance threshold was chosen as P.05. RESULTS Baseline Characteristics of Patients One hundred and sixty-two patients entered the active treatment period. Seventy-eight patients were randomized to the captopril group and 84 to the trandolapril group. TABLE 1. DEMOGRAPHICS AND CHARACTERISTICS OF PATIENTS Age (years) Male (%) BMI (kg/m 2 ) Hypertension duration (years) SBP (mm Hg) DBP (mm Hg) Twenty-nine patients (16 in the captopril group and 13 in the trandolapril group) were excluded from the compliance analysis due to withdrawals for adverse events (10 patients), lack of pill-box data (8 patients), withdrawals for patients convenience (3 patients), or major protocol violation (8 patients). Analysis was thus performed on 133 patients (62 in the captopril group and 71 in the trandolapril group). The patients demographic and clinical characteristics are indicated in Table 1. All demographic characteristics (except for age) and initial blood pressure data were comparable in both treatment groups. The patients in the captopril group were slightly older than the patients in the trandolapril group (P.046). Overall Compliance The average treatment duration was days in the trandolapril group and days in the captopril group (P.70). The overall compliance assessed by pill-count during the 6-month period was 98.9% in the trandolapril group and 97.6% in the captopril group. This difference was statistically significant (P.049). The same difference was observed when assessed by electronic pill-boxes: 98.9% in the trandolapril group and 97.5% in the captopril group (P.002). Although statistically significant, these differences between the two groups were not clinically relevant: the overall compliance was over 80% in the majority of patients. Whatever the method, the difference in overall compliance between the two groups increased with time as shown in Table 2. No difference was observed during the first 2 months. The results became significant during the next 2 months. This statistical significance increased during the last 2 months. However, a significant time treatment interaction was only observed for electronic pill-box data (P.02). Assessment of Daily Compliance by Electronic Pill- Boxes Missed Doses The distribution of missed doses is presented in Figure 1. In the trandolapril group, the patients missed 2.6% of doses (5 doses) during the 6-month treatment and 15.4% of patients forgot more than 10% of doses. In the captopril group,
4 AJH FEBRUARY 2000 VOL. 13, NO. 2 COMPLIANCE AND TREATMENT REGIMEN 187 TABLE 2. COMPARISON OF OVERALL COMPLIANCE OVER TIME, ASSESSED BY PILL COUNT OR ELECTRONIC PILL-BOX Overall Compliance (%), Pill-Count Overall Compliance (%), Electronic Pill-Box Day 0 Day ( ) 97.6 ( ) ( ) 97.5 ( ).002 Day 0 Day ( ) 98.3 ( ) ( ) 99.1 ( ).51 Day 60 Day ( ) 97.5 ( ) ( ) 97.7 ( ).01 Day 120 Day ( ) 97.3 ( ) ( ) 96.7 ( ).0005 Time treatment interaction Data are expressed as median (10th and 90th percentiles). the patients missed 3.3% of doses (12 doses) and 22.5% of patients forgot more than 10% of doses. The between-group comparison is shown in Table 3: during the 6-month treatment, the difference was close to significance (P.06). However, a time treatment interaction was found (P.03). The difference between the two groups became highly significant the last 2 months (P.003). Delayed Doses The distribution of delayed doses is presented in Figure 2. In the trandolapril group, the patients had 1.8% of the doses delayed (3 doses) and 8.4% of patients delayed more than 10% of doses. In the captopril group, the patients had 11.7% of the doses delayed (41 doses) and 59.7% of patients delayed more than 10% of doses. As shown in Table 3, the between-group difference was highly significant throughout the whole study (P.0001). Correct Dosing Period The percentage of correct dosing periods during the study was 94.0% in the trandolapril group and 78.1% in the captopril group (P.0001). This difference was observed throughout the study (Table 3). These results remained unchanged when adjusted for age. FIGURE 1. Distribution of patients according to the percentage of missed doses during the 6-month period.
5 188 ANDREJAK ET AL AJH FEBRUARY 2000 VOL. 13, NO. 2 TABLE 3. ASSESSMENT OF DAILY COMPLIANCE BY ELECTRONIC PILL-BOX Missed Doses (%) Delayed Doses (%) Correct Dosing Periods (%) Day 0 Day (0 14.1) 3.3 ( ) (0 8.2) 11.7 (5 31.3) ( ) 78.1 ( ).0001 Day 0 Day (0 11.8) 1.8 (0 12.5) (0 8.2) 11.7 ( ) ( ) 80.6 ( ).0001 Day 60 Day (0 12.5) 2.8 (0 17.1) (0 7.9) 13.7 ( ) ( ) 77.8 ( ).0001 Day 120 Day (0 12.5) 4.3 ( ) (0 7.1) 11.4 ( ) ( ) 77.5 ( ).0001 Time treatment interaction Data are expressed as median (10th and 90th percentiles). Antihypertensive Efficiency An addition of furosemide was needed for 40% of patients in the captopril group as well as for 46% of patients in the trandolapril group (NS). At the end of the 6-month period, the SBP decrease was mm Hg in the captopril group as opposed to mm Hg in the trandolapril group (P.22). The DBP decrease was respectively mm Hg and mm Hg (P.14). In the trandolapril group 58% of patients were responders (DBP 90 mm Hg or DBP fall 10 mm Hg), while 45% of patients responded to captopril (P.15). The percentage of normalized patients in each treatment group is shown in Table 4. At the end of the study, 41% of patients in the trandolapril group and 27% in the captopril group (NS) had their blood pressure normalized (SBP 140 and DBP 90 mm Hg). Safety The percentage of patients with adverse events was not statistically different in the two groups: 6.7% in the captopril group and 2.2% in the trandolapril group. DISCUSSION In the present study, we assessed patterns of compliance in hypertensive patients treated over 6 months. The overall compliance during that 6-month study assessed either by pill-count or by electronic pill-box was over 95%. Similar results were found in short- FIGURE 2. Distribution of patients according to the percentage of delayed doses during the 6-month period.
6 AJH FEBRUARY 2000 VOL. 13, NO. 2 COMPLIANCE AND TREATMENT REGIMEN 189 TABLE 4. EVALUATION OF BLOOD PRESSURE NORMALIZATION, N 71 (% of patients), N 62 (% of patients) P SBP 140 mm Hg NS DBP 90 mm Hg SBP 140 mmh and DBP 90 mm Hg NS term studies where compliance ranged 82% 95% after 4 10 weeks of treatment. 11,12,15,16 However, long-term compliance has been reported to be lower. After a 6-month follow-up, Sackett et al 17 reported that only 57% of patients took more than 80% of the prescribed doses. Following a 12-month study, Guerrero et al 18 found that compliance declined with time. However, Leenen et al reported a high degree of compliance in patients treated during 20 weeks by either amlodipine or diltiazem. 19 The nearly optimal compliance found in our study can be explained by the following facts: 1. The fact that patients had the electronic pill-box fully explained as a means of following their treatment may have encouraged them to be more compliant. It has been previously reported that the patients compliance increased from 78% 91% when information concerning data recording by the pill dispenser was provided The participation in a randomized well-controlled clinical trial may have led the investigators to select the most compliant patients. Consequently, the rate of compliance that we found was probably overestimated. 3. The withdrawals for adverse events or for the patients convenience were excluded from the analysis. Those patients were, however, the more susceptible to poor compliance. The result of the analysis revealed a significant difference in compliance with therapy between the two treatment groups that clearly favored the trandolapril group. Seeing that a) captopril and trandolapril both belong to the same therapeutic class, ie, ACE inhibitors; b) they were shown to have a similar tolerance in this study; and c) the withdrawals were excluded from the analysis, this difference is therefore most likely to be related to the daily regimen. Although crude, pill-count exhibited a significant between-group difference after 2 months of treatment. However, results were more consistent when using parameters derived from the Medication Event Monitoring System. When assessed by the correct dosing period method, compliance was 78.1% in the twice daily group, as opposed to 94.0% in the once daily group (P.0001). It is logical to believe that compliance is related to the number of prescribed daily doses. Indeed it was easily demonstrated that compliance improved from a three or four times daily regimen to a once daily regimen However, in those studies, no difference in compliance was found between once and twice daily regimens. Three recent studies using MEMS have shown a lower compliance for the twice daily regimen compared with the once daily. 15,19,23 Detry et al, 15 using a parameter close to our correct dosing period, showed that compliance with amlodipine once daily was superior to slowrelease nifedipine twice daily (85% v 64%, P.001). In a similar manner, the percentage of days with correct number of doses taken was significantly higher in patients receiving amlodipine once daily (90%) when compared with patients receiving diltiazem twice daily (82%, P.01). 19 Determining of the number of correct dosing periods depends on the number of missed doses as well as the delayed ones. Obviously the weight of the number of delayed doses plays a leading part in this determination. The number of delayed doses is markedly increased in the twice daily regimen (11.7% v 1.8%, P.0001). The definition of a delayed dose varies from one study to another. The chosen threshold may be expressed either in hours (eg, 26 h for once daily dosages) or in the percentage of the theoretical interval of drug intake (eg, 25%). The latter is readily used as it allows a single definition whatever the drug regimen. 24 However, it might appear unfair, seeing that the delay allocated for each drug intake for a twice daily regimen is half that of a once daily regimen. In the present study, a dose was defined as delayed when the box opening occurred with a delay of 8.5% of the theoretical interval of the drug intake (13 h for a twice a day regimen and 26 h for a once a day regimen). The number of missed doses is marginally increased in the twice daily regimen (3.3% v 2.6%, P.06). However, the betweengroup difference increased with time. At the end of the study, the percentage of missed doses was twice that in the captopril group (4.3% v 2.1%, P.0003). Increasing compliance using once daily antihypertensive drugs may lead to a better blood pressure control. 2 In the SHEP pilot study, it has been shown that compliance 80% was associated with a greater probability of achieving target blood pressure reduction. 25 Mallion et al 11 found a significant correlation between single daily compliance assessed by electronic pill-box and blood pressure control. In our study, we failed to demonstrate a relationship between compliance and blood pressure decrease. However, this could be explained by the discrepancy between the single blood pressure evaluation and the daily compliance evaluation throughout a 6-month period. In addition, we did not find a difference in
7 190 ANDREJAK ET AL AJH FEBRUARY 2000 VOL. 13, NO. 2 blood pressure control between the two groups, whereas their 6-month compliance significantly differed. This might be explained by an increase in compliance in both groups during the few days preceding the visits, as the compliance to drug therapy is known to be better during the days before a consultation. 16 CONCLUSION In this 6-month study, the electronic pill-box allowed refined analysis of compliance of hypertensive patients. Using this device, the present study has shown that patient compliance with once daily trandolapril was higher than with twice daily captopril. The between-group difference is mainly explained by an increase in delayed doses in the twice daily group. REFERENCES 1. Sackett DL, Gibson ES, Taylor DW, et al: Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;1: Meredith PA: Therapeutic implications of drug holidays. Eur Heart J 1996;17(suppl A): Houston MC: Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116: Psaty JM, Koepsell TD, Wagner EH, et al: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263: Rangno RE, Langlois S: Comparison of withdrawal phenomena after propanolol, metoprolol and pindolol. Am Heart J 1982;104: Weber MA: Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. J Cardiovasc Pharmacol 1980; 2(suppl 1): Pullar T, Kumar S, Tindal H, et al: Time to stop counting the tablets? Clin Pharmacol Ther 1989;46: Rudd P, Byyny RL, Zachary V, et al: Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1988;1: Stewart M: The validity of an interview to assess a patient s drug taking. Am J Prev Med 1987;3: Kruse W, Weber E: Dynamics of drug regimen compliance: its assessment by microprocessor-base monitoring. Eur J Clin Pharmacol 1990;38: Mallion JM, Meilhac B, Tremel F, et al: Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol 1992;19(suppl 2):S41 S Mallion JM, Dutrey-Dupagne C, Vaur L, et al: Benefits of electronic pill-boxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996;14: Vaur L, Vaisse B, Genès N, et al: Use of electronic pill-boxes to assess risk of poor treatment compliance: results of a large scale trial. Am J Hypertens 1999;12: Jamieson MJ, Webster J, Witte K, et al: An evaluation of thea&dua-751 semi-automated cuff-oscillometric sphygmomanometer. J Hypertens 1990;8: Detry JMR, Black P, De Backer G, et al: The Belgian Collaborative Study Group: Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1995;47: Rudd P, Ahmed S, Zachary AS, et al: Improved compliance measures: applications in an ambulatory hypertensive trial. Clin Pharmacol Ther 1990;48: Sackett DL, Haynes RB, Gibson ES, et al: Patient compliance with antihypertensive regimens. Patients Council. Health Educ 1978;1: Guerrero D, Rudd P, Bryant-Kosling C, et al: Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertens 1993;6: Leenen FHH, Wilson TW, Bolli P, et al: Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13: Cramer JA, Mattson RH, Prevey ML, et al: How often is medication taken as prescribed? A novel assessment technique. JAMA 1979;261: Eisen SA, Miller DK, Woodward RS, et al: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150: Fujii J, Seki A: Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens 1985;3(suppl 1): Waeber B, Erne P, Saxenhofer H, etal: Useofdrug with more than a twenty-four-hour duration of action. J Hypertens 1994;12(suppl 3):S67 S Lee JY, Kuseck JW, Greene PG, et al: Assessing medication adherence by pill count and electronic monitoring in the African American study of kidney disease and hypertension (AASK) pilot study. Am J Hypertens 1996;9: Black DM, Brand RJ, Greenlick M, et al: Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program. J Gerontol 1987;42:
Many interventional trials have demonstrated
AJH 1998;11:165 173 Short-Term Effects of Withdrawing Angiotensin Converting Enzyme Inhibitor Therapy on Home Self-Measured Blood Pressure in Hypertensive Patients Laurent Vaur, Guillaume Bobrie, Claire
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationThere is convincing evidence in clinical studies
AJH 1998;11:1413 1417 Reliability of Reporting Self-Measured Blood Pressure Values by Hypertensive Patients Thomas Mengden, Rosa Maria Hernandez Medina, Belen Beltran, Elena Alvarez, Karin Kraft, and Hans
More informationValidation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension
Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010 Short title: Validation
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationEfficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationAJH 2000;13: by the American Journal of Hypertension, Ltd /00/$20.00
AJH 2000;13:632 639 Comparison of Three Blood Pressure Measurement Methods for the Evaluation of Two Antihypertensive Drugs: Feasibility, Agreement, and Reproducibility of Blood Pressure Response Stéphanie
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHOW CONSISTENT ARE THE BLOOD PRESSURE AND PULSE RATE MEASUREMENTS OF THE ELECTRONIC BP APPARATUS AND THE MANUAL SPHYGMOMANOMETER
HOW CONSISTENT ARE THE BLOOD PRESSURE AND PULSE RATE MEASUREMENTS OF THE ELECTRONIC BP APPARATUS AND THE MANUAL SPHYGMOMANOMETER Naser KA. Teaching Hospital Peradeniya, Peradeniya, Sri Lanka Zawahir S
More informationIJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EVALUATION OF COMPLIANCE AND BLOOD PRESSURE REDUCTION IN PATIENTS TREATED WITH AMLODIPINE
More informationORIGINAL INVESTIGATION. Is Isolated Home Hypertension as Opposed to Isolated Office Hypertension a Sign of Greater Cardiovascular Risk?
ORIGINAL INVESTIGATION Is Isolated Home as Opposed to Isolated Office a Sign of Greater Cardiovascular Risk? Guillaume Bobrie, MD; Nathalie Genès, MD; Laurent Vaur, MD; Pierre Clerson, MD; Bernard Vaisse,
More informationThe management of hypertension has become
AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationDIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.
DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio
More informationImprovement of drug adherence using single pill combinations:
Improvement of drug adherence using single pill combinations: what is the evidence? Prof. Michel Burnier Service of Nephrology and Hypertension, CHUV, Lausanne, Switzerland Potentialcauses of non-adherence
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationVivencio Barri os1 Objective Carlos Escobar 1 Ángel Navarro 2, Albert o Calderón1 & Luis M Ruilope 3; Methods on behalf of the ELECTRA Investigators
RESEARCH ARTICLE Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationAccording to the Centers for Disease Control and Prevention,1
n review article n Effect of Medication Dosing Frequency on Adherence in Chronic Diseases Sameer D. Saini, MD, MS; Philip Schoenfeld, MD, MSEd, MSc; Kellee Kaulback, MISt; and Marla C. Dubinsky, MD Objective:
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationTHE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)
THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute
More informationTRIple pill vs. Usual care Management for Patients with mild-to-moderate Hypertension
TRIple pill vs. Usual care Management for Patients with mild-to-moderate Hypertension The TRIUMPH study Dr Ruth Webster, PhD, MBBS, MIPH, BMedSc Global control rates for hypertension BP < 140/90 among
More informationDoes masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?
O R I G I N A L A R T I C L E Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? I. Aksoy, J. Deinum, J.W.M. Lenders, Th. Thien *# Department of
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationMethods DEVICES AND TECHNOLOGY
DEVICES AND TECHNOLOGY Validation of the Omron HEM-907 device for blood pressure measurement Mohamed A. El Assaad, Jirar A. Topouchian, Bernadette M. Darné and Roland G. Asmar Background The aim of this
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More information1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany
Page 1 of 9 Validation of the TONOPORT VI ambulatory blood pressure monitor, according to the European Society of Hypertension International Protocol revision 2010 Michael Abou-Dakn 1, Cornelius Döhmen
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationELECTRONIC MONITORS IN PATIENTS WITH CARDIOVASCULAR MEDICATION: A PILOT STUDY IN PRIMARY CARE
INTERVENTION EFFECT OF ELECTRONIC MONITORS IN PATIENTS WITH CARDIOVASCULAR MEDICATION: A PILOT STUDY IN PRIMARY CARE Andreas Zeller University Hospital Basel & Esther Ramseier Family Practice Oberwil Introduction
More informationEchocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?
Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationChapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,
Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Devices and technology 261 Validation of the ROSSMAX blood pressure measuring monitor according to the European Society of Hypertension International Protocol for Validation of Blood Pressure Measuring
More informationByvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationValidity of four indirect methods to measure adherence in primary care hypertensives
(2007) 21, 579 584 & 2007 Nature Publishing Group All rights reserved 0950-9240/07 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Validity of four indirect methods to measure adherence in primary care hypertensives
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL
CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationIRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationMedication compliance and serum lipid changes in the Helsinki
Br. J. clin. Pharmac. (1991), 32, 409415 Medication compliance and serum lipid changes in the Helsinki Heart Study HANNA MAENPAA, 0. P. HEINONEN & V. MANNINEN First Department of Medicine, University of
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationValidation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension
Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension M. EL ASSAAD, J. TOPOUCHIAN, G. LABAKI, R. ASMAR L Institut
More informationModule 3.2. Management of hypertension at primary health care
Module 3.2 Management of hypertension at primary health care What s inside Introduction Learning outcomes Topics covered Competency Teaching and learning activities Background information Introduction
More informationDEVICES AND TECHNOLOGY
DEVICES AND TECHNOLOGY Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor James M. Wright ab, Gurdial S. Mattu a, Thomas L. Perry Jr ab, Mark E. Gelfer
More informationConcentration-Effect Relationships and Implications for Trough-to-Peak Ratio
AJH 1996;9:66S-70S Concentration-Effect Relationships and Implications for Trough-to-Peak Ratio Peter A. Meredith and Henry L. Elliott The guidelines on trough-to-peak ratio identified an index of the
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationand bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].
Devices and technology 37 Validation of the A&D UM-11 professional hybrid device for office blood pressure measurement according to the International Protocol George S. Stergiou, Periklis P. Giovas, Charilaos
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More information